Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Intra-Cellular Therapies Inc shares valued at $1,829,178 were purchased by ALEXANDRIA VENTURE INVESTMENTS on Sep 06 ’24. At $73.17 per share, ALEXANDRIA VENTURE INVESTMENTS acquired 25,000 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Mates Sharon sold 35,604 shares, netting a total of over 2,583,884 in proceeds. Following the sale of shares at $72.57 each, the insider now holds 1,070,329 shares.
Before that, Mates Sharon had sold 34,396 shares from its account. In a trade valued at $2,505,351, the Chairman and CEO traded Intra-Cellular Therapies Inc shares for $72.84 each. Upon closing the transaction, the insider’s holdings decreased to 34,396 shares, worth approximately $96.88 million.
As published in a research note from Piper Sandler on September 06, 2024, Intra-Cellular Therapies Inc [ITCI] has been rated up from a Neutral to an Overweight and the price target has been revised to $92 from $68. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in early January. As of December 11, 2023, TD Cowen has initiated its “an Outperform” rating for ITCI. Earlier on April 20, 2023, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for ITCI stock.
Analyzing ITCI Stock Performance
During the last five days, there has been a surge of approximately 6.80%. Over the course of the year, Intra-Cellular Therapies Inc shares have jumped approximately 26.38%. Shares of the company reached a 52-week high of $91.68 on 11/07/24 and a 52-week low of $62.78 on 02/22/24. A 50-day SMA is recorded $76.40, while a 200-day SMA reached $72.35. Nevertheless, trading volume fell to 0.59 million shares from 0.7 million shares the previous day.
Support And Resistance Levels for Intra-Cellular Therapies Inc (ITCI)
According to the 24-hour chart, there is a support level at 89.39, which, if violated, would cause prices to drop to 88.26. In the upper region, resistance lies at 91.66. The next price resistance is at 92.80. RSI (Relative Strength Index) is 78.50 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 7.86, which suggests the price will increase in the coming days. Percent R is at 6.91%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
